Skip to main content

Dahan Michel's Form 4 filing

Akebia Therapeutics, Inc.AKBA · filed May 14, 2024

Accession no.
0001562180-24-004025
Filed
May 14, 2024
Trade date
May 13, 2024
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 1 non-derivative transaction. Open-market sales total $43.9K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Dahan MichelCIK 0001669737Officer (SVP, Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 13, 2024Common StockSSaleDisposed−34,840$1.26−$43,898.4672,092Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)